Clicky

Mental Health Charity National Collaboration for Youth Mental Health’s “Say NO to Bullying Anyone” bullying for any reason – race, orientation, family, someone’s past – leads to depression, anxiety, isolation and hopelessness

OTTAWA, Ontario–(BUSINESS WIRE)–The National Collaboration for Youth Mental Health (NCYMH) says bullying because of race, gender, orientation, someone’s family, someone’s past causes serious mental health challenges such as anxiety, depression, low self esteem, isolation and ultimately post traumatic stress order and the Mental Health Charity, NCYMH, launches a Daily Say NO to bullying campaign on […]

Mental Health Charity National Collaboration for Youth Mental Health’s “Say NO to Bullying Anyone” bullying for any reason – race, orientation, family, someone’s past – leads to depression, anxiety, isolation and hopelessness Read More »

Lockdowns Led to Spikes in Depression, Weight Loss, Cognitive Decline in Nursing Home Residents

Families of nursing home residents have spent the past year appealing to policymakers that COVID-19 lockdowns were having a significantly negative effect on their loved ones’ health — and a new study put some sobering numbers on the physical impact of loneliness. The proportion of residents experiencing unexpected weight loss accelerated by 150% during the

Lockdowns Led to Spikes in Depression, Weight Loss, Cognitive Decline in Nursing Home Residents Read More »

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder

CHATHAM, N.J., March 22, 2021 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals, Inc. Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that it has received the official minutes from a Type B pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) on its development plan for TNX-601

Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA on TNX-601 CR for the Treatment of Major Depressive Disorder Read More »

Multiple Sclerosis and Major Depressive Disorder Share Little Genetic Liability

No evidence from a Mendelian randomization analysis supported a genetic liability associated with multiple sclerosis (MS) susceptibility among patients with major depressive disorder (MDD). These findings were published in the Multiple Sclerosis Journal. Study researchers sourced data from recent meta-analyses of MDD (total: n=807,553 individuals; cases: n=246,363) and MS (cases: n=47,429; control group participants: n=68,374),

Multiple Sclerosis and Major Depressive Disorder Share Little Genetic Liability Read More »

Research in metaphors enables better understanding of depression and patients’ needs

“You have to win the battle against depression”, “what counts is not surrendering” and “this is not a short road” are examples of conceptual metaphors typically used to describe experiences and issues associated with disorders like depression. Such expressions allude to abstract concepts but do so using familiar terms that enable better understanding of the

Research in metaphors enables better understanding of depression and patients’ needs Read More »

VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines Nasdaq:VTGN

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, announced today that data highlighting the proposed mechanism

VistaGen’s Poster Presentation at the Anxiety and Depression Association of America’s 2021 Annual Conference Differentiates PH94B’s Mechanism of Action from Highly-Addictive Benzodiazepines Nasdaq:VTGN Read More »